DISCOVER

Vascepa®

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

Vascepa


The History of Vascepa

Development of Vascepa leveraged Amarin’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The clinical development of Vascepa challenged previously established norms and created an important new drug that has the potential to significantly improve patient care for millions of patients. The use of Vascepa is now supported by over 200 issued patents worldwide and by FDA designation of the active ingredient in Vascepa as a new chemical entity under its regulatory regime. This designation from FDA was the first recognition that no FDA-approved drug has the same active ingredient as Vascepa.

MORE

recent news


Nov 14, 2019

Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial MORE

Nov 14, 2019

Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking New Indication for Vascepa® (Icosapent Ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$21.49
Change:
+0.55
Date:
4:00 PM EDT, Nov 14, 2019
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe